Before joining Numab in 2011, Tea was Head of pharmacokinetics & pharmacodynamics at Esbatech from 2004 until 2011. She led the development of bio-analytical methods in drug discovery and development, as well as the pharmacodynamic and pharmacokinetic characterization of antibody fragment lead candidates. Tea led preclinical discovery and development projects in the field of ophthalmology, and was instrumental in the discovery and the development of ESBA1008 (now RTH258), a best-in-class anti-VEGF scFv for the treatment of age-related macular edema. Tea is an inventor on a number of patents and patent applications and has published in leading peer-reviewed journals. Tea holds an MSc in Molecular Biology and Immunology from the University of Zurich, and obtained her PhD in Molecular Biology from the University of Zurich in 2004.
Molecular Biology